Cargando…
Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097682/ https://www.ncbi.nlm.nih.gov/pubmed/37045875 http://dx.doi.org/10.1038/s41523-023-00532-3 |
| _version_ | 1785024623530737664 |
|---|---|
| author | Dieci, Maria Vittoria Bisagni, Giancarlo Bartolini, Stefania Frassoldati, Antonio Vicini, Roberto Balduzzi, Sara D’amico, Roberto Conte, Pierfranco Guarneri, Valentina |
| author_facet | Dieci, Maria Vittoria Bisagni, Giancarlo Bartolini, Stefania Frassoldati, Antonio Vicini, Roberto Balduzzi, Sara D’amico, Roberto Conte, Pierfranco Guarneri, Valentina |
| author_sort | Dieci, Maria Vittoria |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10097682 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100976822023-04-14 Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial Dieci, Maria Vittoria Bisagni, Giancarlo Bartolini, Stefania Frassoldati, Antonio Vicini, Roberto Balduzzi, Sara D’amico, Roberto Conte, Pierfranco Guarneri, Valentina NPJ Breast Cancer Author Correction Nature Publishing Group UK 2023-04-12 /pmc/articles/PMC10097682/ /pubmed/37045875 http://dx.doi.org/10.1038/s41523-023-00532-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Dieci, Maria Vittoria Bisagni, Giancarlo Bartolini, Stefania Frassoldati, Antonio Vicini, Roberto Balduzzi, Sara D’amico, Roberto Conte, Pierfranco Guarneri, Valentina Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial |
| title | Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial |
| title_full | Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial |
| title_fullStr | Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial |
| title_full_unstemmed | Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial |
| title_short | Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial |
| title_sort | author correction: type of adjuvant endocrine therapy and disease-free survival in patients with early hr-positive/her2-positive bc: analysis from the phase iii randomized shorther trial |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097682/ https://www.ncbi.nlm.nih.gov/pubmed/37045875 http://dx.doi.org/10.1038/s41523-023-00532-3 |
| work_keys_str_mv | AT diecimariavittoria authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT bisagnigiancarlo authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT bartolinistefania authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT frassoldatiantonio authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT viciniroberto authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT balduzzisara authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT damicoroberto authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT contepierfranco authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial AT guarnerivalentina authorcorrectiontypeofadjuvantendocrinetherapyanddiseasefreesurvivalinpatientswithearlyhrpositiveher2positivebcanalysisfromthephaseiiirandomizedshorthertrial |